LipoScience Company Profile (NASDAQ:LPDX)

Analyst Ratings

Consensus Ratings for LipoScience (NASDAQ:LPDX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for LipoScience (NASDAQ:LPDX)
Show:
DateFirmActionRatingPrice TargetActions
8/13/2014Piper Jaffray Cos.Lower Price TargetNeutral$3.80 -> $3.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2014 forward)

Earnings

Earnings History for LipoScience (NASDAQ:LPDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/12/2014Q3 14($0.26)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.24)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q1 14($0.19)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2014Q413($0.24)($0.17)$12.71 million$12.72 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for LipoScience (NASDAQ:LPDX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for LipoScience (NASDAQ:LPDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for LipoScience (NASDAQ:LPDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/4/2013Daniel LevangieDirectorBuy10,000$4.17$41,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013E. Duffy McdonaldVPSell12,731$4.07$51,815.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013James HurleyDirectorBuy5,100$3.91$19,941.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013Robert Greczyn, Jr.CEOBuy10,000$4.15$41,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2013Buzz BensonDirectorBuy50,000$9.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2013Three Arch Capital LpMajor ShareholderBuy215,000$9.00$1,935,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for LipoScience (NASDAQ:LPDX)
DateHeadline
01/27/15 07:00 AMMiraculins: Pioneering a New Approach to Diabetes Screening - [Accesswire] - WHITEFISH, MT / ACCESSWIRE / January 27, 2015 / Diabetes affects nearly 30 million U.S. citizens - or roughly 10% of the population - with about 27% of those cases going undiagnosed, according to the American ...
09/25/14 09:27 AMUS STOCKS-Cantor turns bearish on U.S. equities -

Social

About LipoScience

LipoScience logoLipoScience, Inc. is a vitro diagnostic company. The Company's diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LPDX
  • CUSIP: 53630M10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $5
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-0.93 EPS
  • Next Year EPS Consensus Estimate: $-0.84 EPS
Additional Links:
LipoScience (NASDAQ:LPDX) Chart for Sunday, July, 31, 2016